https://m2.mtmt.hu/ hun 2026-09-23 05:24 JournalArticle 32644498 VALIDATED true Corrigendum In: FRONTIERS IN ONCOLOGY 13 Paper: 1203745 , 1 p. (2023) [33803824] 0 false 2026-06-15T12:36:56.373+0000 2026-01-29T16:45:50.557+0000 2022-02-03T13:34:47.996+0000 true 10022176 Laczik Cecilia /api/admin/10022176 Admin Laczik Cecilia (SE_AOK_1Patológia_Admin5_LC, admin) true 10022176 2026-06-15T12:33:43.819+0000 2026-06-15T12:33:43.819+0000 2025-03-06T11:43:06.559+0000 true 10022176 Laczik Cecilia /api/admin/10022176 Admin Laczik Cecilia (SE_AOK_1Patológia_Admin5_LC, admin) true 10022176 Admin 10063514 /api/admin/10063514 Mikola Katalin (MTMT 3, admin) Mikola Katalin true 10063514 true 2026-01-21T13:12:53.998+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Váncza, Lóránd true true /api/journal/10025358 REVIEWED FRONTIERS IN ONCOLOGY 2234-943X 2234-943X true false 10025358 false 10025358 true 2234-943X 2234-943X Journal FOREIGN 12 819883 819883 18 2022 The extracellular matrix proteoglycan SPOCK1 is increasingly recognized as a contributor to the development and progression of cancers. Here, we study how SPOCK1, which is present in non-tumorous hepatocytes at low concentrations, promotes the development and progression of malignant hepatocellular tumors. Although SPOCK1 is an extracellular matrix proteoglycan, its concentration increases in the cytoplasm of hepatocytes starting with very low expression in the normal cells and then appearing in much higher quantities in cells of cirrhotic human liver and hepatocellular carcinoma. This observation is similar to that observed after diethylnitrosamine induction of mouse hepatocarcinogenesis. Furthermore, syndecan-1, the major proteoglycan of the liver, and SPOCK1 are in inverse correlation in the course of these events. In hepatoma cell lines, the cytoplasmic SPOCK1 colocalized with mitochondrial markers, such as MitoTracker and TOMM20, a characteristic protein of the outer membrane of the mitochondrion and could be detected in the cell nucleus. SPOCK1 downregulation of hepatoma cell lines by siRNA inhibited cell proliferation, upregulated p21 and p27, and interfered with pAkt and CDK4 expression. A tyrosine kinase array revealed that inhibition of SPOCK1 in the liver cancer cells altered MAPK signaling and downregulated several members of the Sarc family, all related to the aggressivity of the hepatoma cell lines. These studies support the idea that SPOCK1 enhancement in the liver is an active contributor to human and rodent hepatocarcinogenesis and cancer progression. However, its mitochondrial localization raises the possibility that it has a currently unidentified physiological function in normal hepatocytes. Funding 2010960 /api/funding/2010960 (67925) Támogató: NKFIH false true Funding 2010961 /api/funding/2010961 Orszagos Tudomanyos Kutatasi Alapprogramok(100904) false true Funding 2010962 /api/funding/2010962 (119283) Támogató: NKFIH false true Funding 2010963 /api/funding/2010963 (138673) false true Funding 2010964 /api/funding/2010964 European Union Horizon 2020 Marie Skłodowska-Curie Actions Research and Innovation Staff Exchange...(645756) false true Funding 2010965 /api/funding/2010965 Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP false true true 2022 true true true false true false GOLD 2026-06-15 true https://doi.org/10.3389/fonc.2022.819883 16 0 16 9 7 15 16 16 15 16 16 9 9 9 7 0 16 9 16 9 0 6 6 Folyóiratcikk Journal Article 24 16 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 3 1 3 1 2023 0 7 3 7 3 2024 0 0 0 0 0 2025 0 4 3 4 3 2026 0 2 2 2 2 Q2 false 10027508,10026672,10009505 false false false 2022-02-02T13:35:03.560+0000 Akadémikus bibliográfia; I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I); II. Sz. Patológiai Intézet (SE / AOK / I); Információs Technológiai és Bionikai Kar (PPKE); Szerves Kémiai Intézet (MTA TTK) 12 31 5 12 0 true 10063514 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 100420359 /api/authorship/100420359 Váncza, Lóránd [Váncza, Lóránd (Onkológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 1 0.083 true false false Author 10072608 /api/author/10072608 Váncza Lóránd (Onkológia) Váncza Lóránd true true Váncza Lóránd true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420360 /api/authorship/100420360 Karászi, Katalin [Karászi, Katalin (Molekuláris biológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 2 0.083 false false false Author 10061005 /api/author/10061005 Karászi Katalin (Molekuláris biológia) Karászi Katalin true 10061005 true Karászi Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420361 /api/authorship/100420361 Péterfia, Bálint [Péterfia, Bálint (Molekuláris biológia), szerző] Információs Technológiai és Bionikai Kar (PPKE) 3 0.083 false false false Author 10026672 /api/author/10026672 Péterfia Bálint (Molekuláris biológia) Péterfia Bálint true 10026672 true Péterfia Bálint true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420362 /api/authorship/100420362 Turiák, Lilla [Turiák, Lilla (tömegspektrometri...), szerző] Szerves Kémiai Intézet (MTA TTK) 4 0.083333336 false false false Author 10024570 /api/author/10024570 Turiák Lilla (tömegspektrometria, proteomika) Turiák Lilla true 10024570 true Turiák Lilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420363 /api/authorship/100420363 Dezső, Katalin [Dezső, Katalin (Patológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 5 0.083 false false false Author 10024599 /api/author/10024599 Dezső Katalin (Patológia) Dezső Katalin true 10024599 true Dezső Katalin true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420364 /api/authorship/100420364 Sebestyén, Anna [Sebestyén, Anna (Tumorbiológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 6 0.083 false false false Author 10000745 /api/author/10000745 Sebestyén Anna (Tumorbiológia) Sebestyén Anna true 10000745 true Sebestyén Anna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420365 /api/authorship/100420365 Reszegi, Andrea [Reszegi, Andrea (Molekuláris biológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 7 0.083 false false false Author 10063277 /api/author/10063277 Reszegi Andrea (Molekuláris biológia) Reszegi Andrea true 10063277 true Reszegi Andrea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420366 /api/authorship/100420366 Petővári, Gábor [Petővári, Gábor (Tumorbiológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 8 0.083 false false false Author 10051987 /api/author/10051987 Petővári Gábor (Tumorbiológia) Petővári Gábor true 10051987 true Petővári Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420367 /api/authorship/100420367 Kiss, András [Kiss, András (Pathológia, hepat...), szerző] II. Sz. Patológiai Intézet (SE / AOK / I) 9 0.083 false false false Author 10000554 /api/author/10000554 Kiss András (Pathológia, hepatocarcinogenesis) Kiss András true 10000554 true Kiss András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420368 /api/authorship/100420368 Schaff, Zsuzsanna [Schaff, Zsuzsa (Patológia), szerző] II. Sz. Patológiai Intézet (SE / AOK / I) 10 0.083 false false false Author 1323309 /api/author/1323309 Schaff Zsuzsa (Patológia) Schaff Zsuzsa true 1323309 true Schaff Zsuzsanna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420369 /api/authorship/100420369 Baghy, Kornélia [Baghy, Kornélia (Molekuláris biológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 11 0.083 false false false Author 10027508 /api/author/10027508 Baghy Kornélia (Molekuláris biológia) Baghy Kornélia true 10027508 true Baghy Kornélia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100420370 /api/authorship/100420370 Kovalszky, Ilona ✉ [Kovalszky, Ilona (Onkológia), szerző] I. Sz. Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 12 0.083 false true true Author 10009505 /api/author/10009505 Kovalszky Ilona (Onkológia) Kovalszky Ilona true 10009505 true Kovalszky Ilona true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true Institute 19040 /api/institute/19040 Akadémikus bibliográfia [2016-] 0 false false true Akadémikus bibliográfia Bibliografy of Hungarian of Academy of Sciences' academicians true 19040 true PublicationIdentifier 20526652 /api/publicationidentifier/20526652 DOI: 10.3389/fonc.2022.819883 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3389/fonc.2022.819883 https://doi.org/10.3389/fonc.2022.819883 false true PublicationIdentifier 20750442 /api/publicationidentifier/20750442 WoS: 000759874300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000759874300001 https://www.webofscience.com/wos/woscc/full-record/000759874300001 true true PublicationIdentifier 20750441 /api/publicationidentifier/20750441 Scopus: 85124882114 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85124882114 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85124882114 true true PublicationIdentifier 20750446 /api/publicationidentifier/20750446 PubMed: 35186754 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 35186754 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35186754&dopt=Abstract true true SjrRating 11283984 /api/sjrrating/11283984 sjr:Q2 (2022) Scopus - Cancer Research FRONTIERS IN ONCOLOGY 2234-943X 2234-943X 84 0.49 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1306 /api/classificationexternal/1306 Scopus - Cancer Research true 1306 true Q2 DIRECT true true Reference 27468766 /api/reference/27468766 1. You 2017: Cancer Incidence Increasing Globally: The Role of Relaxed Natural Selection., Evolutionary Appl, 11, DOI: 10.1111/eva.12523 1 10.1111/eva.12523 false true Reference 27468767 /api/reference/27468767 2. Valkenburg 2018: Targeting the Tumour Stroma to Improve Cancer Therapy., Nat Rev Clin Oncol, 15, DOI: 10.1038/s41571-018-0007-1 2 10.1038/s41571-018-0007-1 false true Reference 27468768 /api/reference/27468768 3. Pape 2020: Cancer-Associated Fibroblasts Mediate Cancer Progression and Remodel the Tumouroid Stroma., Br J Cancer, 123, DOI: 10.1038/s41416-020-0973-9 3 10.1038/s41416-020-0973-9 false true Reference 27468769 /api/reference/27468769 4. Sebestyén 2000: Cytokine Regulation of Syndecan Expression in Cells of Liver Origin., Cytokine, 12, DOI: 10.1006/cyto.2000.0754 4 10.1006/cyto.2000.0754 false true Reference 27468770 /api/reference/27468770 5. Regős 2018: Syndecan-1 Inhibits Early Stages of Liver Fibrogenesis by Interfering With Tgfβ1 Action and Upregulating MMP14., Matrix Biol J Int Soc Matrix Biol, DOI: 10.1016/j.matbio.2018.02.008 5 10.1016/j.matbio.2018.02.008 false true Reference 27468771 /api/reference/27468771 6. Roskams 1996: Heparan Sulfate Proteoglycan Expression in Chronic Cholestatic Human Liver Diseases., Hepatol (Baltimore Md), 24, DOI: 10.1053/jhep.1996.v24.pm0008781318 6 10.1053/jhep.1996.v24.pm0008781318 false true Reference 27468772 /api/reference/27468772 7. Xia 2021: Serum Syndecan-4 is Associated With Nonalcoholic Fatty Liver Disease., J Digestive Dis, 22, DOI: 10.1111/1751-2980.13037 7 10.1111/1751-2980.13037 false true Reference 27468773 /api/reference/27468773 8. Regős 2020: Syndecan-1 in Liver Diseases., Pathol Oncol Res POR, 26, DOI: 10.1007/s12253-019-00617-0 8 10.1007/s12253-019-00617-0 false true Reference 27468774 /api/reference/27468774 9. Reszegi 2021: Overexpression of Human Syndecan-1 Protects Against the Diethylnitrosamine-Induced Hepatocarcinogenesis in Mice., Cancers, 13, p. 1548, DOI: 10.3390/cancers13071548 9 10.3390/cancers13071548 false true Reference 27468775 /api/reference/27468775 10. Filmus 2013: Glypican-3: A Marker and a Therapeutic Target in Hepatocellular Carcinoma., FEBS J, 280, DOI: 10.1111/febs.12126 10 10.1111/febs.12126 false true Reference 27468776 /api/reference/27468776 11. Guo 2020: Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma., J Cancer, 11, DOI: 10.7150/jca.39972 11 10.7150/jca.39972 false true Reference 27468777 /api/reference/27468777 12. Tátrai 2010: Quantitative and Qualitative Alterations of Heparan Sulfate in Fibrogenic Liver Diseases and Hepatocellular Cancer., J Histochem Cytochem Off J Histochem Soc, 58, DOI: 10.1369/jhc.2010.955161 12 10.1369/jhc.2010.955161 false true Reference 27468778 /api/reference/27468778 13. Bukong 2016: Versican: A Novel Modulator of Hepatic Fibrosis., Lab invest; J Tech Methods Pathol, 96, DOI: 10.1038/labinvest.2015.152 13 10.1038/labinvest.2015.152 false true Reference 27468779 /api/reference/27468779 14. Bonnet 1992: Characterization of a Human Seminal Plasma Glycosaminoglycan-Bearing Polypeptide., Biochem J, 288, DOI: 10.1042/bj2880565 14 10.1042/bj2880565 false true Reference 27468780 /api/reference/27468780 15. Charbonnier 1997: [Cloning of Testican/SPOCK in Man and Mouse. Neuromuscular Expression Perspectives in Pathology]., C R Seances Soc Biol Fil, 191 15 false true Reference 27468781 /api/reference/27468781 16. Cifuentes-Diaz 2000: Regulated Expression of the Proteoglycan SPOCK in the Neuromuscular System., Mech Dev, 94, DOI: 10.1016/s0925-4773(00)00285-9 16 10.1016/s0925-4773(00)00285-9 false true Reference 27468782 /api/reference/27468782 17. Bonnet 1996: Structure and Cellular Distribution of Mouse Brain Testican. Association With the Postsynaptic Area of Hippocampus Pyramidal Cells., J Biol Chem, 271, DOI: 10.1074/jbc.271.8.4373 17 10.1074/jbc.271.8.4373 false true Reference 27468783 /api/reference/27468783 18. Hausser 2004: Testican-1, an Inhibitor of Pro-MMP-2 Activation, Is Expressed in Cartilage., Osteoarthritis Cartilage, 12, DOI: 10.1016/j.joca.2004.07.008 18 10.1016/j.joca.2004.07.008 false true Reference 27468784 /api/reference/27468784 19. Edgell 2004: Testican-1: A Differentially Expressed Proteoglycan With Protease Inhibiting Activities., Int Rev Cytol, 236, DOI: 10.1016/s0074-7696(04)36003-1 19 10.1016/s0074-7696(04)36003-1 false true Reference 27468785 /api/reference/27468785 20. Lee 2018: Testican-1, as a Novel Diagnosis of Sepsis., J Cell Biochem, 119, DOI: 10.1002/jcb.26661 20 10.1002/jcb.26661 false true Reference 27468786 /api/reference/27468786 21. Chen 2018: SPOCK1 Promotes the Invasion and Metastasis of Gastric Cancer Through Slug-Induced Epithelial-Mesenchymal Transition., J Cell Mol Med, 22, p. 797, DOI: 10.1111/jcmm.13357 21 10.1111/jcmm.13357 false true Reference 27468787 /api/reference/27468787 22. Chen 2016: SPOCK1 Promotes Tumor Growth and Metastasis in Human Prostate Cancer., Drug Des Devel Ther, 10, DOI: 10.2147/dddt.S91321 22 10.2147/dddt.S91321 false true Reference 27468788 /api/reference/27468788 23. Shu 2015: SPOCK1 as a Potential Cancer Prognostic Marker Promotes the Proliferation and Metastasis of Gallbladder Cancer Cells by Activating the PI3K/AKT Pathway., Mol Cancer, 14, DOI: 10.1186/s12943-014-0276-y 23 10.1186/s12943-014-0276-y false true Reference 27468789 /api/reference/27468789 24. Yu 2016: SPOCK1 Is Upregulated in Recurrent Glioblastoma and Contributes to Metastasis and Temozolomide Resistance., Cell Prolif, 49, p. 195, DOI: 10.1111/cpr.12241 24 10.1111/cpr.12241 false true Reference 27468790 /api/reference/27468790 25. Veenstra 2017: Stromal SPOCK1 Supports Invasive Pancreatic Cancer Growth., Mol Oncol, 11, DOI: 10.1002/1878-0261.12073 25 10.1002/1878-0261.12073 false true Reference 27468791 /api/reference/27468791 26. Fan 2016: SPOCK1 Is a Novel Transforming Growth Factor-β-Induced Myoepithelial Marker That Enhances Invasion and Correlates With Poor Prognosis in Breast Cancer., PloS One, 11, DOI: 10.1371/journal.pone.0162933 26 10.1371/journal.pone.0162933 false true Reference 27468792 /api/reference/27468792 27. Han 2021: Multiomic Analysis of the Function of SPOCK1 Across Cancers: An Integrated Bioinformatics Approach., J Int Med Res, 49, DOI: 10.1177/0300060520962659 27 10.1177/0300060520962659 false true Reference 27468793 /api/reference/27468793 28. Wang 2018: Reduced SPOCK1 Expression Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Migration Through Wnt/β-Catenin Signaling., Eur Rev Med Pharmacol Sci, 22, DOI: 10.26355/eurrev_201802_14288 28 10.26355/eurrev_201802_14288 false true Reference 27468794 /api/reference/27468794 29. Li 2013: SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice., Gastroenterology, 144, p. 179, DOI: 10.1053/j.gastro.2012.09.042 29 10.1053/j.gastro.2012.09.042 false true Reference 27468795 /api/reference/27468795 30. Annaval 2020: Heparan Sulfate Proteoglycans Biosynthesis and Post Synthesis Mechanisms Combine Few Enzymes and Few Core Proteins to Generate Extensive Structural and Functional Diversity., Molecules, 25, p. 4215, DOI: 10.3390/molecules25184215 30 10.3390/molecules25184215 false true Reference 27468796 /api/reference/27468796 31. Seglen 1976: Preparation of Isolated Rat Liver Cells., Methods Cell Biol, 13, p. 29, DOI: 10.1016/s0091-679x(08)61797-5 31 10.1016/s0091-679x(08)61797-5 false true Reference 27468797 /api/reference/27468797 32. Xiong 2021: Diversity Roles of CHD1L in Normal Cell Function and Tumorigenesis., Biomark Res, 9, p. 16, DOI: 10.1186/s40364-021-00269-w 32 10.1186/s40364-021-00269-w false true Reference 27468798 /api/reference/27468798 33. Marimuthu 2011: Gene Expression Profiling of Gastric Cancer., J Proteomics Bioinf, 4, p. 74, DOI: 10.4172/jpb.1000170 33 10.4172/jpb.1000170 false true Reference 27468799 /api/reference/27468799 34. Korpetinou 2015: Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines., BioMed Res Int, 2015, DOI: 10.1155/2015/690721 34 10.1155/2015/690721 false true Reference 27468800 /api/reference/27468800 35. Alshargabi 2020: SPOCK1 Induces Adipose Tissue Maturation: New Insights Into the Function of SPOCK1 in Metabolism., Biochem Biophys Res Commun, 533, DOI: 10.1016/j.bbrc.2020.09.129 35 10.1016/j.bbrc.2020.09.129 false true Reference 27468801 /api/reference/27468801 36. Du 2020: SPOCK1 Overexpression Induced by Platelet-Derived Growth Factor-BB Promotes Hepatic Stellate Cell Activation and Liver Fibrosis Through the Integrin α5β1/PI3K/Akt Signaling Pathway., Lab invest; J Tech Methods Pathol, 100, DOI: 10.1038/s41374-020-0425-4 36 10.1038/s41374-020-0425-4 false true Reference 27468802 /api/reference/27468802 37. Chen 2019: High SPOCK1 Expression Is Associated With Advanced Stage, T Value, and Gleason Grade in Prostate Cancer., Med (Kaunas), 55, p. 343, DOI: 10.3390/medicina55070343 37 10.3390/medicina55070343 false true Reference 27468803 /api/reference/27468803 38. Xu 2020: SPOCK1/SIX1axis Promotes Breast Cancer Progression by Activating AKT/mTOR Signaling., Aging, 13, DOI: 10.18632/aging.202231 38 10.18632/aging.202231 false true Reference 27468804 /api/reference/27468804 39. Gao 2019: SPOCK1 Contributes to the Third-Generation EGFR Tyrosine Kinase Inhibitors Resistance in Lung Cancer., J Cell Biochem, 120, DOI: 10.1002/jcb.28523 39 10.1002/jcb.28523 false true Reference 27468805 /api/reference/27468805 40. Singh 2017: RNAi Screen Identifies Essential Regulators of Human Brain Metastasis-Initiating Cells., Acta Neuropathol, 134, DOI: 10.1007/s00401-017-1757-z 40 10.1007/s00401-017-1757-z false true Reference 27468806 /api/reference/27468806 41. Li 2020: A Potential Prognostic Marker and Therapeutic Target: SPOCK1 Promotes the Proliferation, Metastasis, and Apoptosis of Pancreatic Ductal Adenocarcinoma Cells., J Cell Biochem, 121, DOI: 10.1002/jcb.29320 41 10.1002/jcb.29320 false true Reference 27468807 /api/reference/27468807 42. Cheng 2013: CHD1L: A Novel Oncogene., Mol Cancer, 12, DOI: 10.1186/1476-4598-12-170 42 10.1186/1476-4598-12-170 false true Reference 27468808 /api/reference/27468808 43. Steven 2016: Control of CREB Expression in Tumors: From Molecular Mechanisms and Signal Transduction Pathways to Therapeutic Target., Oncotarget, 7, DOI: 10.18632/oncotarget.7721 43 10.18632/oncotarget.7721 false true Reference 27468809 /api/reference/27468809 44. Johannessen 2007: Multisite Phosphorylation of the cAMP Response Element-Binding Protein (CREB) by a Diversity of Protein Kinases., Front Biosci, 12, DOI: 10.2741/2190 44 10.2741/2190 false true Reference 27468810 /api/reference/27468810 45. Wang 2018: cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia., Front Mol Neurosci, 11, DOI: 10.3389/fnmol.2018.00255 45 10.3389/fnmol.2018.00255 false true Reference 27468811 /api/reference/27468811 46. Scheiblecker 2020: CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment., Pharm (Basel), 13, p. 418, DOI: 10.3390/ph13120418 46 10.3390/ph13120418 false true Reference 27468812 /api/reference/27468812 47. Kumar 2015: Pharmacology of Src Family Kinases and Therapeutic Implications of Their Modulators., Fundam Clin Pharmacol, 29, DOI: 10.1111/fcp.12097 47 10.1111/fcp.12097 false true Reference 27468813 /api/reference/27468813 48. Klein 1997: Activation of Src Family Kinases by Hepatitis B Virus HBx Protein and Coupled Signaling to Ras., Mol Cell Biol, 17, DOI: 10.1128/mcb.17.11.6427 48 10.1128/mcb.17.11.6427 false true Reference 27468814 /api/reference/27468814 49. Yang 2021: C-Src Promotes the Growth and Tumorigenesis of Hepatocellular Carcinoma via the Hippo Signaling Pathway., Life Sci, 264, DOI: 10.1016/j.lfs.2020.118711 49 10.1016/j.lfs.2020.118711 false true Reference 27468815 /api/reference/27468815 50. Hunter 2020: C-Src Kinase Impairs the Expression of Mitochondrial OXPHOS Complexes in Liver Cancer., Cell Signal, 72, DOI: 10.1016/j.cellsig.2020.109651 50 10.1016/j.cellsig.2020.109651 false true Reference 27468816 /api/reference/27468816 51. Nonomura 2007: Identification of C-Yes Expression in the Nuclei of Hepatocellular Carcinoma Cells: Involvement in the Early Stages of Hepatocarcinogenesis., Int J Oncol, 30, DOI: 10.3892/ijo.30.1.105 51 10.3892/ijo.30.1.105 false true Reference 27468817 /api/reference/27468817 52. Feng 2006: Activation of C-Yes in Hepatocellular Carcinoma: A Preliminary Study., World J Gastroenterol, 12, DOI: 10.3748/wjg.v12.i35.5743 52 10.3748/wjg.v12.i35.5743 false true Reference 27468818 /api/reference/27468818 53. Tan 2015: Up-Regulation of microRNA-210 Inhibits Proliferation of Hepatocellular Carcinoma Cells by Targeting YES1., World J Gastroenterol, 21, DOI: 10.3748/wjg.v21.i46.13030 53 10.3748/wjg.v21.i46.13030 false true Reference 27468819 /api/reference/27468819 54. Stanford 2009: Syndecan-1 Is the Primary Heparan Sulfate Proteoglycan Mediating Hepatic Clearance of Triglyceride-Rich Lipoproteins in Mice., J Clin Invest, 119, DOI: 10.1172/jci38251 54 10.1172/jci38251 false true Reference 27468820 /api/reference/27468820 55. Charchanti 2021: Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis., In Vivo (Athens Greece), 35, DOI: 10.21873/invivo.12264 55 10.21873/invivo.12264 false true Reference 27468821 /api/reference/27468821 56. Shi 2013: Syndecan-1 Serves as the Major Receptor for Attachment of Hepatitis C Virus to the Surfaces of Hepatocytes., J Virol, 87, DOI: 10.1128/jvi.03475-12 56 10.1128/jvi.03475-12 false true Reference 27468822 /api/reference/27468822 57. Lefèvre 2014: Syndecan 4 Is Involved in Mediating HCV Entry Through Interaction With Lipoviral Particle-Associated Apolipoprotein E., PloS One, 9, DOI: 10.1371/journal.pone.0095550 57 10.1371/journal.pone.0095550 false true Reference 27468823 /api/reference/27468823 58. Nijmeijer 2020: Syndecan 4 Upregulation on Activated Langerhans Cells Counteracts Langerin Restriction to Facilitate Hepatitis C Virus Transmission., Front Immunol, 11, DOI: 10.3389/fimmu.2020.00503 58 10.3389/fimmu.2020.00503 false true Reference 27468824 /api/reference/27468824 59. Astudillo 2014: Syndecan-4 Inhibits Wnt/β-Catenin Signaling Through Regulation of Low-Density-Lipoprotein Receptor-Related Protein (LRP6) and R-Spondin 3., Int J Biochem Cell Biol, 46, DOI: 10.1016/j.biocel.2013.11.012 59 10.1016/j.biocel.2013.11.012 false true Reference 27468825 /api/reference/27468825 60. Kon 2008: Syndecan-4 Protects Against Osteopontin-Mediated Acute Hepatic Injury by Masking Functional Domains of Osteopontin., J Exp Med, 205, p. 25, DOI: 10.1084/jem.20071324 60 10.1084/jem.20071324 false true Reference 27468826 /api/reference/27468826 61. Takahashi 2021: Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors., Int J Mol Sci, 22, p. 5780, DOI: 10.3390/ijms22115780 61 10.3390/ijms22115780 false true Reference 27468827 /api/reference/27468827 62. Tátrai 2006: Agrin, a Novel Basement Membrane Component in Human and Rat Liver, Accumulates in Cirrhosis and Hepatocellular Carcinoma., Lab invest; J Tech Methods Pathol, 86, DOI: 10.1038/labinvest.3700475 62 10.1038/labinvest.3700475 false true Reference 27468828 /api/reference/27468828 63. Kolluri 2019: The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer., Front Oncol, 9, DOI: 10.3389/fonc.2019.00708 63 10.3389/fonc.2019.00708 false true Reference 27468829 /api/reference/27468829 64. Chakraborty 2015: An Oncogenic Role of Agrin in Regulating Focal Adhesion Integrity in Hepatocellular Carcinoma., Nat Commun, 6, p. 6184, DOI: 10.1038/ncomms7184 64 10.1038/ncomms7184 false true Reference 27468830 /api/reference/27468830 65. Chakraborty 2017: Agrin as a Mechanotransduction Signal Regulating YAP Through the Hippo Pathway., Cell Rep, 18, DOI: 10.1016/j.celrep.2017.02.041 65 10.1016/j.celrep.2017.02.041 false true Reference 27468831 /api/reference/27468831 66. Yang 2016: SPOCK1 Promotes the Proliferation, Migration and Invasion of Glioma Cells Through PI3K/AKT and Wnt/β-Catenin Signaling Pathways., Oncol Rep, 35, DOI: 10.3892/or.2016.4757 66 10.3892/or.2016.4757 false true Reference 27468832 /api/reference/27468832 67. Sun 2020: SPOCK1 Involvement in Epithelial-To-Mesenchymal Transition: A New Target in Cancer Therapy., Cancer Manage Res, 12, DOI: 10.2147/cmar.S249754 67 10.2147/cmar.S249754 false true /api/publication/32644498 Váncza Lóránd et al. SPOCK1 Promotes the Development of Hepatocellular Carcinoma. (2022) FRONTIERS IN ONCOLOGY 2234-943X 2234-943X 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10072608"><a href="/gui2/?type=authors&mode=browse&sel=10072608" target="_blank">Váncza Lóránd (<span class="authorship-author-name">Váncza Lóránd</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10061005"><a href="/gui2/?type=authors&mode=browse&sel=10061005" target="_blank">Karászi Katalin (<span class="authorship-author-name">Karászi Katalin</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026672"><a href="/gui2/?type=authors&mode=browse&sel=10026672" target="_blank">Péterfia Bálint (<span class="authorship-author-name">Péterfia Bálint</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Pázmány Péter Katolikus Egyetem">PPKE</span>/Információs Technológiai és Bionikai Kar</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024570"><a href="/gui2/?type=authors&mode=browse&sel=10024570" target="_blank">Turiák Lilla (<span class="authorship-author-name">Turiák Lilla</span> <span class="authorAux-mtmt"> tömegspektrometria, proteomika</span>) </a> </span> <span class="author-affil"><span title="MTA Természettudományi Kutatóközpont">MTA TTK</span>/Szerves Kémiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024599"><a href="/gui2/?type=authors&mode=browse&sel=10024599" target="_blank">Dezső Katalin (<span class="authorship-author-name">Dezső Katalin</span> <span class="authorAux-mtmt"> Patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000745"><a href="/gui2/?type=authors&mode=browse&sel=10000745" target="_blank">Sebestyén Anna (<span class="authorship-author-name">Sebestyén Anna</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10063277"><a href="/gui2/?type=authors&mode=browse&sel=10063277" target="_blank">Reszegi Andrea (<span class="authorship-author-name">Reszegi Andrea</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10051987"><a href="/gui2/?type=authors&mode=browse&sel=10051987" target="_blank">Petővári Gábor (<span class="authorship-author-name">Petővári Gábor</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000554"><a href="/gui2/?type=authors&mode=browse&sel=10000554" target="_blank">Kiss András (<span class="authorship-author-name">Kiss András</span> <span class="authorAux-mtmt"> Pathológia, hepatocarcinogenesis</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/II. Sz. Patológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="1323309"><a href="/gui2/?type=authors&mode=browse&sel=1323309" target="_blank">Schaff Zsuzsanna (<span class="authorship-author-name">Schaff Zsuzsa</span> <span class="authorAux-mtmt"> Patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/II. Sz. Patológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10027508"><a href="/gui2/?type=authors&mode=browse&sel=10027508" target="_blank">Baghy Kornélia (<span class="authorship-author-name">Baghy Kornélia</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10009505"><a href="/gui2/?type=authors&mode=browse&sel=10009505" target="_blank">Kovalszky Ilona ✉ (<span class="authorship-author-name">Kovalszky Ilona</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/I. Sz. Patológiai és Kísérleti Rákkutató Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32644498" target="_blank">SPOCK1 Promotes the Development of Hepatocellular Carcinoma</a></div> <div> <span class="journal-title">FRONTIERS IN ONCOLOGY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2234-943X">2234-943X</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2234-943X">2234-943X</a>)</span>: <span class="journal-volume">12</span> <span class="page"> Paper 819883. 18 p. </span> <span class="year">(2022)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3389/fonc.2022.819883" target="_blank" href="https://doi.org/10.3389/fonc.2022.819883"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000759874300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000759874300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85124882114" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85124882114"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="35186754" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35186754&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 16</span> | Független: 9 | Függő: 7 | Nem jelölt: 0 | WoS jelölt: 16 | Scopus jelölt:&nbsp;15 | WoS/Scopus jelölt:&nbsp;16 | DOI jelölt:&nbsp;16 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32644498&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 6 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32644498</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="special-affiliations"> Speciális affiliáció: Akadémikus bibliográfia </div> <div class="funder"> (67925) Támogató: NKFIH, Orszagos Tudomanyos Kutatasi Alapprogramok(100904), (119283) Támogató: NKFIH, (138673), European Union Horizon 2020 Marie Skłodowska-Curie Actions Research and Innovation Staff Exchange...(645756), Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP </div> <div class="lastModified">Utolsó módosítás: 2026.01.29. 17:45 Mikola Katalin (MTMT 3, admin) </div> <div class="lockedBy">Központi kezelésű 2026.01.21. 14:12 Mikola Katalin (MTMT 3, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Corrigendum In: FRONTIERS IN ONCOLOGY 13 Paper: 1203745 , 1 p. (2023) [33803824]</pre> </div></div>